mbl-hcv1
mAbexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2009 (NCT00952263)
Timeline
Indications
Mechanism of action
- Genome polyproteinINHIBITOR
Genome polyprotein inhibitor
- Hepatitis C virusImmunity, passive
Hepatitis C virus immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109438 ↗
Also known as
- mbl-hcv1
- mbl-hcv-1
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01532908 | Phase 2 | May 1, 2012 | MassBiologics |
| NCT01121185 | Phase 2 | Jun 1, 2010 | MassBiologics, University of Massachusetts |
| NCT00952263 | Phase 1 | Jul 1, 2009 | Davita Clinical Research, MassBiologics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MassBiologics | Academic/Hospital | 3 | 3 | 2 | 2009 |
| Davita Clinical Research | For profit | 1 | 0 | 1 | 2009 |
| University of Massachusetts | Academic/Hospital | 1 | 0 | 1 | 2010 |
3 organizations
Page 1 / 1